Document Detail

Low-dose spironolactone prevents apoptosis repressor with caspase recruitment domain degradation during myocardial infarction.
MedLine Citation:
PMID:  22508833     Owner:  NLM     Status:  MEDLINE    
Low-dose mineralocorticoid receptor antagonists reduce morbidity and mortality in patients with heart failure and myocardial infarction, despite normal plasma aldosterone levels. Since apoptosis plays an important role in heart failure and postinfarction left ventricular remodeling, we examined whether low-dose mineralocorticoid receptor antagonists modulate cardiomyocyte death by regulating the apoptosis repressor protein apoptosis repressor with caspase recruitment domain to lessen the extent of apoptosis. Hearts from adult male Sprague-Dawley rats were subjected to regional ischemia followed by reperfusion ex vivo, with mineralocorticoid receptor antagonists added to perfusates before ischemia. Low-dose spironolactone (10 nmol/L) or eplerenone (100 nmol/L) significantly reduced infarct size. Spironolactone also prevented cleavage of the apoptotic chromatin condensation inducer in the nucleus and of the inhibitor of caspase-activated DNAse induced by ischemia-reperfusion, thereby abolishing chromatin condensation and internucleosomal cleavage. Ischemia-reperfusion-induced activation of caspases 2, 3, and 9, but not caspase 8, was prevented by spironolactone, suggesting targeted regulation of the intrinsic pathway. Low-dose spironolactone and eplerenone prevented loss of the apoptosis repressor with the caspase recruitment domain and reduced myocyte death. In H9c2 cells, mineralocorticoid receptor activation by aldosterone resulted in apoptosis repressor with caspase recruitment domain degradation and enhanced apoptosis; these actions were prevented by coadministration of spironolactone. Using a triple lysine mutant we identified that aldosterone enhances posttranscriptional degradation of the apoptosis repressor with a caspase recruitment domain via the ubiquitin-proteasomal pathway. Our data demonstrate that low-dose mineralocorticoid receptor antagonists reduce infarct size and apoptosis in the reperfused myocardium by preventing the apoptosis repressor with caspase recruitment domain degradation.
Thi Yen Loan Le; Mahidi Mardini; Viive M Howell; John W Funder; Anthony W Ashton; Anastasia S Mihailidou
Related Documents :
19303033 - Experimental pathology of local tissue damage induced by bothrops asper snake venom.
19632213 - New implications of the proteolytic balance between matrix metalloproteinases and their...
3604053 - Pasteurella haemolytica cytotoxin: relative susceptibility of bovine leucocytes.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-04-16
Journal Detail:
Title:  Hypertension     Volume:  59     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-17     Completed Date:  2012-07-25     Revised Date:  2013-11-25    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1164-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects
Apoptosis Regulatory Proteins / genetics,  metabolism*
Caspase 2 / metabolism
Caspase 3 / metabolism
Caspase 9 / metabolism
Cell Line
Dose-Response Relationship, Drug
Enzyme Activation / drug effects
Mineralocorticoid Receptor Antagonists / pharmacology
Muscle Proteins / genetics,  metabolism*
Myocardial Infarction / genetics,  metabolism,  prevention & control*
Proteolysis / drug effects
RNA Interference
Rats, Sprague-Dawley
Receptors, Mineralocorticoid / metabolism
Reverse Transcriptase Polymerase Chain Reaction
Spironolactone / analogs & derivatives,  pharmacology*
Reg. No./Substance:
0/Apoptosis Regulatory Proteins; 0/Mineralocorticoid Receptor Antagonists; 0/Muscle Proteins; 0/Nol3 protein, rat; 0/Receptors, Mineralocorticoid; 0/caspase-activated DNase inhibitor; 27O7W4T232/Spironolactone; 6995V82D0B/eplerenone; EC 3.4.22.-/Caspase 2; EC 3.4.22.-/Caspase 3; EC 3.4.22.-/Caspase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart...
Next Document:  Mechanisms of carbon monoxide attenuation of tubuloglomerular feedback.